Next-generation approaches to Alzheimer’s disease and integrating the role of Artificial Intelligence

Read full text Summarise with VIRAT
Authors: P Rajyalakshmi Devi, Alvakounda Rani, Dasari Navya
Cited by: 0
References: 36

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

AD is the most common neurodegenerative disorder causing dementia and, therefore, a rapidly growing global health burden, affecting more than 55 million people worldwide at present. This figure is anticipated to increase sharply over the next 10-20 years due to the aging of the population, predominantly in China, the US, India, and Europe. AD pathophysiology includes aggregation of amyloid-β plaques, tau neurofibrillary tangles, synaptic dysfunction, mitochondrial injury, oxidative stress, neuroinflammation, and progressive loss of neurons. Genetic risk factors that include the mutations of APP, PSEN1, and PSEN2, which are correlated with the APOE ε4 allele and enhance the disease susceptibility. Biomarkers, including those in cerebrospinal fluid and blood (amyloid-β and tau), in concert with neuroimaging PET and MRI, have improved early diagnosis, disease monitoring, and stratification of patients. All present therapies remain largely symptomatic, whereas disease-modifying immunotherapies have constraints in efficacy and access. Recent novel therapeutic approaches, such as stem cell therapy, gene therapy, CRISPR-Cas, peptidomimetics, tau-targeting peptides, the gut-brain axis, and targeted therapy through advanced drug delivery systems, are making new therapeutic opportunities. However, it is significant that artificial intelligence is revolutionizing AD research and management today by anticipating the disease, integrating biomarkers, target identification, repositioning of drugs, and tailoring treatment strategies using artificial intelligence. This article attempts to compile all the modern global epidemiological trends, pathophysiological mechanisms, advancements in biomarkers, innovative therapies, and artificial intelligence that are helping shape the future of AD management strategies.

Fields of Study & Subjects

Alzheimer's disease research and treatments Dementia and Cognitive Impairment Research Neuroinflammation and Neurodegeneration Mechanisms

Publication details

Journal / source
International Journal of Pharmacology and Clinical Research
Volume
8
Issue
2
Pages
24–32
Publication date
1 February 2026
Language
EN